Localization of human sarcoma with radiolabeled monoclonal antibody--a follow-up report.
A group of 16 sarcoma patients with suspected advanced disease were studied with a radiolabeled anti-sarcoma monoclonal antibody (mAb 19-24) in an attempt to localize tumor deposits. All 16 patients received 125I-mAb 19-24 and then had external-probe analysis and imaging performed. Confirmation of tumor deposits was done at surgery or by autopsy. Tissues were studied in surgical patients when possible and analyzed for radioactivity, and tumor-to-blood ratios ranged from 0.6 to 36.8. In conjunction with the patients previously studied, probe results had an overall sensitivity of 83.3% and an overall specificity of 100%; scintigraphic results showed an overall sensitivity of 78.9% and an overall specificity of 100%. Radiolabeled mAb 19-24 may be developed into a useful tool for clinical immunodetection of sarcoma deposits.
Greager
J A
JA
Division of Surgical Oncology, University of Illinois College of Medicine, Chicago 60612.
Chao
T C
TC
Brown
J M
JM
Pavel
D G
DG
Blend
M J
MJ
Das Gupta
T K
TK
D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D005260:Female; D005500:Follow-Up Studies; D015902:Gamma Cameras; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging / Q000379:methods; D012509:Sarcoma / Q000000981:diagnostic imaging*; D012983:Soft Tissue Neoplasms / Q000000981:diagnostic imaging*
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes